Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 13
- 主要终点
- Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
研究概览
简要总结
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with histological confirmed epithelia ovarian cancer
- •Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- •Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- •FFPE tumor tissue available
排除标准
- •Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- •Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
研究组 & 干预措施
Ovarian cancer patients
with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
干预措施: Drug Response Predictor® (DRP) (Device)
结局指标
主要结局
Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
时间窗: up to 2 years
based on FFPE ovarian cancer tissue
次要结局
- Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer(up to 2 years)